ScholarIQanswers from OpenAlex & ORCID
Naomi V. Dahl
ResearcherPublications, citations & collaboration network
Naomi V. Dahl is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Naomi V. Dahl have?
ScholarIQindexed works
Naomi V. Dahl has 78 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Naomi V. Dahl have?
ScholarIQcitation count
Naomi V. Dahl has 2,130 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Naomi V. Dahl?
ScholarIQh-index
Naomi V. Dahl has an h-index of 21 in OpenAlex.
What is the i10-index of Naomi V. Dahl?
ScholarIQi10-index
Naomi V. Dahl has an i10-index of 32 in OpenAlex.
What is the ORCID of Naomi V. Dahl?
ScholarIQorcid
The ORCID for Naomi V. Dahl is on the source record.
What is the OpenAlex record for Naomi V. Dahl?
ScholarIQopenalex
The OpenAlex for Naomi V. Dahl is on the source record.
What are the most-cited papers on Naomi V. Dahl?
ScholarIQmost cited works
Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation
Daniel W. Coyne, Toros Kapoian, Wadi N. Suki, Ajay Singh, John Moran, Naomi V. Dahl, Adel R. Rizkala
Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy
David H. Henry, Naomi V. Dahl, Michael Auerbach, Simon Tchekmedyian, Leslie R. Laufman
Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin
Toros Kapoian, Neeta Bahal O’Mara, Ajay Singh, John Moran, Adel R. Rizkala, Robert Geronemus, Robert C. Kopelman, Naomi V. Dahl, Daniel W. Coyne
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia
Michael Auerbach, Jennifer A. Pappadakis, Huzefa Bahrain, Sarah Auerbach, Harold S. Ballard, Naomi V. Dahl
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients
Daniel W. Coyne, Franklin Adkinson, Allen R. Nissenson, Steven Fishbane, Rajiv Agarwal, Joseph W. Eschbach, Beckie Michael, Vaughn W. Folkert, Daniel Batlle, J. Richard Trout, Naomi V. Dahl, Pamela Myirski, Jur Strobos, David G. Warnock